[go: up one dir, main page]

WO2012060790A3 - Formulations de cefpodoxime proxétil dispersibles dans l'eau - Google Patents

Formulations de cefpodoxime proxétil dispersibles dans l'eau Download PDF

Info

Publication number
WO2012060790A3
WO2012060790A3 PCT/TR2011/000255 TR2011000255W WO2012060790A3 WO 2012060790 A3 WO2012060790 A3 WO 2012060790A3 TR 2011000255 W TR2011000255 W TR 2011000255W WO 2012060790 A3 WO2012060790 A3 WO 2012060790A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
water dispersible
cefpodoxime proxetil
proxetil
cefpodoxime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000255
Other languages
English (en)
Other versions
WO2012060790A2 (fr
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012060790A2 publication Critical patent/WO2012060790A2/fr
Publication of WO2012060790A3 publication Critical patent/WO2012060790A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations pharmaceutiques comprenant du cefpodoxime proxétil.
PCT/TR2011/000255 2010-11-05 2011-11-03 Formulations de cefpodoxime proxétil dispersibles dans l'eau Ceased WO2012060790A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/09168 2010-11-05
TR2010/09168A TR201009168A2 (tr) 2010-11-05 2010-11-05 Suda dağılan sefpodoksim proksetil formülasyonları.

Publications (2)

Publication Number Publication Date
WO2012060790A2 WO2012060790A2 (fr) 2012-05-10
WO2012060790A3 true WO2012060790A3 (fr) 2012-09-20

Family

ID=45446166

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000251 Ceased WO2012060786A2 (fr) 2010-11-05 2011-11-03 Formulations de proxétil cefpodoxime comprenant un agent de viscosité
PCT/TR2011/000255 Ceased WO2012060790A2 (fr) 2010-11-05 2011-11-03 Formulations de cefpodoxime proxétil dispersibles dans l'eau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000251 Ceased WO2012060786A2 (fr) 2010-11-05 2011-11-03 Formulations de proxétil cefpodoxime comprenant un agent de viscosité

Country Status (2)

Country Link
TR (1) TR201009168A2 (fr)
WO (2) WO2012060786A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2833872A1 (fr) * 2012-04-04 2015-02-11 Mahmut Bilgic Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique
CN103142506B (zh) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 一种头孢泊肟酯颗粒剂及其制备方法
CN103230367B (zh) * 2013-05-07 2014-11-12 山东罗欣药业集团股份有限公司 一种头孢泊肟酯组合物干混悬剂及其制备方法
MX2017007287A (es) * 2014-12-01 2017-08-25 Sun Pharmaceutical Ind Ltd Composicion de cefpodoxima proxetil de liberacion prolongada.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067943A1 (fr) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Composition pharmaceutique orale de cefpodoxime-proxetil
WO2004004737A1 (fr) * 2002-07-08 2004-01-15 Sankyo Company, Limited Preparation de cephalosporine a administration orale
WO2004006917A1 (fr) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Comprimes dispersibles pour administration par voie orale
WO2007017895A2 (fr) * 2005-05-05 2007-02-15 Lupin Limited Compositions pharmaceutiques stabilisees de cephalosporines
WO2011129792A1 (fr) * 2010-04-13 2011-10-20 Mahmut Bilgic Formulations dispersibles dans l'eau comprenant le cefpodoxime proxétil

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067943A1 (fr) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Composition pharmaceutique orale de cefpodoxime-proxetil
WO2004004737A1 (fr) * 2002-07-08 2004-01-15 Sankyo Company, Limited Preparation de cephalosporine a administration orale
WO2004006917A1 (fr) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Comprimes dispersibles pour administration par voie orale
WO2007017895A2 (fr) * 2005-05-05 2007-02-15 Lupin Limited Compositions pharmaceutiques stabilisees de cephalosporines
WO2011129792A1 (fr) * 2010-04-13 2011-10-20 Mahmut Bilgic Formulations dispersibles dans l'eau comprenant le cefpodoxime proxétil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200416, Derwent World Patents Index; AN 2004-169094, XP002676813 *

Also Published As

Publication number Publication date
WO2012060790A2 (fr) 2012-05-10
WO2012060786A3 (fr) 2012-07-26
WO2012060786A2 (fr) 2012-05-10
TR201009168A2 (tr) 2012-05-21

Similar Documents

Publication Publication Date Title
IL277110A (en) Immunogenic anti-inflammatory preparations
WO2012042371A3 (fr) Composition pharmaceutique
IL217828B (en) Crystalline molecular complex consisting of zeldronate acid, lysine and water, pharmaceutical compositions containing it and uses thereof
WO2011093824A3 (fr) Formulations effervescentes comprenant du céfaclor
PT2591091E (pt) Método para a preparação de 1,3-propanodiol a partir de sacarose
WO2012064743A3 (fr) Procédés d'amélioration de la fonction cardiaque
WO2012060790A3 (fr) Formulations de cefpodoxime proxétil dispersibles dans l'eau
WO2011029536A3 (fr) Utilisation de céto-énols cycliques pour lutter contre des bactéries pathogènes chez les végétaux
WO2012026907A3 (fr) Préparations de cefpodoxime proxétil
WO2012080176A3 (fr) Compositions pharmaceutiques
WO2012051126A3 (fr) Macrolides antiinflammatoires
WO2011097527A3 (fr) Immunoprotection de fractions thérapeutiques avec des régions fc améliorées
IT1405996B1 (it) Procedimento per la preparazione di 2,5-diaminotoluolo
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
EP2481097A4 (fr) Photodiode du type avalanche
IT1396373B1 (it) Procedimento per la preparazione di fesoterodina.
WO2012004073A3 (fr) UTILISATION DE β-ISOPHORONE COMME SOLVANT
WO2011152805A3 (fr) Composition pharmaceutique comprenant de l'acide clavulanique et du cefpodoxime proxétil
WO2013081563A3 (fr) Formulations de comprimés stables
WO2012026908A3 (fr) Préparations de cefpodoxime proxétil comprenant un agent régulateur de goût
WO2011139250A3 (fr) Formulation hydrodispersable
IT1403154B1 (it) Procedimento per la preparazione di tramezzini di tipo sushi.
FR2941524B1 (fr) L'azimut'heure
WO2011133385A3 (fr) Nouveaux composés à base d'éther et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11805269

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11805269

Country of ref document: EP

Kind code of ref document: A2